News

ALKS 4230, which was formerly referred to as RDB 1450, a novel selective effector cell activator protein designed to preferentially bind and signal through the intermediate affinity interleukin-2

The study, conducted in partnership with Amplion and Biomedtracker, recorded and analyzed 9,985 clinical and regulatory phase transitions, across 1,103 companies. Using clinical trial data from the past

The lead, a reversible BTK inhibitor, offers exciting potential to treat Chronic Lymphocytic Leukaemia (CLL) patients who have become resistant to the gold standard therapy, Imbruvica (ibrutinib). This

IDegLira is a once-daily, single injection fixed combination of insulin degludec (Tresiba) and liraglutide (Victoza) for the treatment of adults with type 2 diabetes. Based on the data

In addition, Lilly could launch an average of two new indications or line extensions for already-approved products per year during that same time period. "We’re pleased to share

Headline results from the 2,802-patient Salford Lung Study (SLS) in COPD showed that the inhaled therapy achieved a superior reduction in exacerbations versus usual care – which included

A total 115 patients were enrolled in the placebo-controlled, randomized, double-blind trial, which evaluated the efficacy and safety of three separate, twice-daily, dosing regimens of Prurisol — 50

Invokamet is a fixed-dose therapy combining canagliflozin and metformin hydrochloride in a single tablet. The drug has now been approved as a first-line treatment for adults with type

This presents the possibility of completing the clinical development program with only one pivotal efficacy study in each of the two indications being focused on by Isofol (colorectal